



## **ANI Pharmaceuticals Announces Launch of Indapamide Tablets**

April 19, 2017

**BAUDETTE, Minnesota (April 19, 2017)** - ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced launch of Indapamide Tablets, 1.25mg and 2.5mg, which is used in the treatment of hypertension and swelling associated with congestive heart failure. The annual U.S. market for Indapamide Tablets is approximately \$9 million, per IMS Health.

Arthur S. Przybyl, ANI's President and CEO stated, "This is the second product that we are launching from the basket of 22 previously marketed generic products that we acquired in July 2015. This launch represents yet another successful manufacturing site transfer and re-commercialization of a previously discontinued ANDA product. We will continue to leverage our U.S. based manufacturing assets as we aim to launch additional products manufactured at these sites in 2017."

### **About Indapamide Tablets**

Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention (swelling) associated with congestive heart failure.

### **About ANI**

ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website [www.anipharmaceuticals.com](http://www.anipharmaceuticals.com).

### **Forward-Looking Statements**

To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company's future operations, products financial position, operating results and prospects, the Company's pipeline or potential markets therefor, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates.

Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may face with respect to importing raw materials; increased competition; acquisitions; contract manufacturing arrangements; delays or failure in obtaining product approval from the U.S. Food and Drug Administration; general business and economic conditions; market trends; products development; regulatory and other approvals and marketing.

More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as its proxy statement. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company's current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events

or otherwise.

For more information about ANI, please contact:

Investor Relations

[IR@anipharma.com](mailto:IR@anipharma.com)